[go: up one dir, main page]

WO2008049657A3 - Utilisation de copolymères de (méth)acrylate dans des formes de médicaments à délivrance retardée pour diminuer les effets de l'éthanol sur la libération de la subtance active - Google Patents

Utilisation de copolymères de (méth)acrylate dans des formes de médicaments à délivrance retardée pour diminuer les effets de l'éthanol sur la libération de la subtance active Download PDF

Info

Publication number
WO2008049657A3
WO2008049657A3 PCT/EP2007/058100 EP2007058100W WO2008049657A3 WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3 EP 2007058100 W EP2007058100 W EP 2007058100W WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
active ingredient
meth
influence
acrylate copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/058100
Other languages
German (de)
English (en)
Other versions
WO2008049657A2 (fr
Inventor
Hans-Ulrich Petereit
Brigitte Skalsky
Diego Gallardo
Manfred Assmus
Andreas Gryczke
Wolfgang Weisbrod
Felix Hofmann
Hans Baer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roehm GmbH Darmstadt
Original Assignee
Evonik Roehm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm GmbH filed Critical Evonik Roehm GmbH
Publication of WO2008049657A2 publication Critical patent/WO2008049657A2/fr
Publication of WO2008049657A3 publication Critical patent/WO2008049657A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de copolymères de (méth)acrylate insolubles dans le suc gastrique dans des formes orales de médicaments à délivrance retardée en tant que partie constitutive de la matrice contenant la substance active dans le but de réduire les effets d'accélération ou de ralentissement de la délivrance de la substance active provoqués par l'éthanol en conditions in vitro.
PCT/EP2007/058100 2006-10-26 2007-08-06 Utilisation de copolymères de (méth)acrylate dans des formes de médicaments à délivrance retardée pour diminuer les effets de l'éthanol sur la libération de la subtance active Ceased WO2008049657A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006051020.8 2006-10-26
DE200610051020 DE102006051020A1 (de) 2006-10-26 2006-10-26 Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung

Publications (2)

Publication Number Publication Date
WO2008049657A2 WO2008049657A2 (fr) 2008-05-02
WO2008049657A3 true WO2008049657A3 (fr) 2008-10-30

Family

ID=38521102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058100 Ceased WO2008049657A2 (fr) 2006-10-26 2007-08-06 Utilisation de copolymères de (méth)acrylate dans des formes de médicaments à délivrance retardée pour diminuer les effets de l'éthanol sur la libération de la subtance active

Country Status (3)

Country Link
DE (1) DE102006051020A1 (fr)
TW (1) TW200833372A (fr)
WO (1) WO2008049657A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187873B1 (fr) 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Médicaments résistant aux abus, procédés d'utilisation et de fabrication
PL2326313T3 (pl) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
BRPI0823096B8 (pt) 2008-09-24 2022-07-05 Evonik Roehm Gmbh composição farmacêutica de opióide de liberação controlada, dependente do ph, com resistência contra a influência do etanol, processo para sua preparação, e seu uso
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
US9730899B2 (en) * 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CN105287434A (zh) * 2009-03-18 2016-02-03 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
BRPI0924427A2 (pt) * 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
ES2642788T3 (es) * 2010-05-10 2017-11-20 Euro-Celtique S.A. Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
HUE033117T2 (en) 2011-06-17 2017-11-28 Evonik Roehm Gmbh A coating composition suitable for coating a pharmaceutical or therapeutic food dosage form
SI2720682T1 (sl) 2011-06-17 2017-05-31 Evonik Roehm Gmbh Sestavek za oplaščenje primeren za farmacevtske ali nutracevtske dozirne oblike
KR101902602B1 (ko) 2011-06-17 2018-09-28 에보니크 룀 게엠베하 에탄올의 영향에 대해 내성을 갖는 위 내성 제약 또는 기능식품 조성물
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
EP3068397A1 (fr) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
JP2022524458A (ja) 2019-03-11 2022-05-02 エボニック オペレーションズ ゲーエムベーハー ポリマーマトリックスを含む剤形

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (fr) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Formulation solide a liberation prolongee/controlee en tant que nouveau systeme d'administration de medicaments a risque reduit de liberation massive
WO2006079550A2 (fr) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Formes posologiques resistant a l'extraction alcoolique
WO2006094083A1 (fr) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Formulations de venlafaxine a liberation controlee
WO2007053698A2 (fr) * 2005-10-31 2007-05-10 Alza Corporation Methodes de reduction de la liberation massive, induite par l'alcool, des formes posologiques orales a liberation soutenue d'opioides
WO2007085024A2 (fr) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Forme dosifiée et méthode d'administration de drogues toxicomanogènes
WO2008011595A2 (fr) * 2006-07-21 2008-01-24 Lab International Srl Système de délivrance hydrophobe empêchant les utilisations abusives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP1301177A2 (fr) * 2000-07-10 2003-04-16 Therics, Inc. Procede et materiaux pour reguler la migration d'un liquide liant dans une poudre
DE10058771A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Coazervierungsverfahren zur Herstellung von verzögert feisetzenden Arzneimitteln
FI1765303T4 (fi) * 2004-07-01 2023-01-31 Väärinkäytöltä suojattu oraalinen tabletti

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (fr) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Formulation solide a liberation prolongee/controlee en tant que nouveau systeme d'administration de medicaments a risque reduit de liberation massive
WO2006079550A2 (fr) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Formes posologiques resistant a l'extraction alcoolique
WO2006094083A1 (fr) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Formulations de venlafaxine a liberation controlee
WO2007053698A2 (fr) * 2005-10-31 2007-05-10 Alza Corporation Methodes de reduction de la liberation massive, induite par l'alcool, des formes posologiques orales a liberation soutenue d'opioides
WO2007085024A2 (fr) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Forme dosifiée et méthode d'administration de drogues toxicomanogènes
WO2008011595A2 (fr) * 2006-07-21 2008-01-24 Lab International Srl Système de délivrance hydrophobe empêchant les utilisations abusives

Also Published As

Publication number Publication date
TW200833372A (en) 2008-08-16
DE102006051020A1 (de) 2008-04-30
WO2008049657A2 (fr) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008049657A3 (fr) Utilisation de copolymères de (méth)acrylate dans des formes de médicaments à délivrance retardée pour diminuer les effets de l'éthanol sur la libération de la subtance active
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2006084164A8 (fr) Systeme d'administration a retention gastrique et a liberation lente
WO2009063222A3 (fr) Compositions solides
SI1906939T1 (sl) Uporaba delno nevtraliziranega anionskega kopolimera (met)akrilata kot oplaščenje za izdelavo zdravila, ki sprošča aktivno učinkovino pri znižanih vrednostih pH
WO2009117130A3 (fr) Formulation à libération prolongée contenant une cire
WO2008061226A3 (fr) Formulations de topiramate à libération prolongée
EP3272337A3 (fr) Comprimés
WO2008052033A3 (fr) Composition d'ibuprofène
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2009051022A3 (fr) Préparation pharmaceutique solide
WO2011101866A3 (fr) Méthode de traitement d'une affection sensible à une thérapie par baclofène
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2011053003A3 (fr) Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg
WO2007138466A3 (fr) Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2009068708A8 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
WO2008005353A3 (fr) Préparations en comprimé à libération immédiate d'un antagoniste des récepteurs de la thrombine
WO2007016284A3 (fr) Preparations/compositions pharmaceutiques de guanfacine destinees a l'administration d'une dose quotidienne unique
WO2007099555A3 (fr) Compositions pharmaceutiques contenant de l'irbésartan
WO2008060546A3 (fr) Formulations orales
WO2007110765A3 (fr) Procedes de preparation d'octreotide
WO2011064797A3 (fr) Compositions pharmaceutiques à libération contrôlée de galantamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2